Hebei Lansheng Biotech Co., Ltd.
Beijing Multigrass Formulation Co., Ltd.

FMC Signs Definitive Agreement to Sell Peroxygens Business to One Equity Partnersqrcode

Dec. 16, 2013

Favorites Print
Forward
Dec. 16, 2013
FMC Corporation has signed a definitive agreement to sell its Peroxygens business to affiliates of One Equity Partners, the private investment arm of J.P. Morgan Chase & Co.  The transaction, valued at approximately $200 million, is expected to close in the first quarter of 2014, subject to customary regulatory approvals and closing conditions.

In April, FMC simplified its organizational structure to focus on three core business segments that better reflect the markets where the company participates and leads, and where it expects to grow in the future. FMC Peroxygens, although a successful business, is not a strategic fit with the company's growth platforms.

"We're pleased to sell our Peroxygens business to a successful and respected investment firm, One Equity Partners," said Pierre Brondeau, president, CEO and chairman of FMC.  "This transaction will help unlock the growth potential of the Peroxygens business with focused attention and investment, while allowing FMC to direct our resources to core segments in crop protection, health and nutrition technologies, alkali chemicals and lithium."

Picture 0/1200

More from AgroNews

Magazine

Annual Review 2020 2020 India Pesticide Suppliers Guide
2020 Market Insight Chinese issue of 2020 Market Insight
2020 CRO & CRAO Manual Chinese issue of 2020 Biologicals Special
Subscribe Comment

Subscribe 

Subscribe Email: *
Name:
Mobile Number:  

Comment  

Picture 0/1200

Subscribe to daily email alerts of AgroNews.